Clinic Semaglutide

Semaglutide Dosage: FDA-Approved Doses, Titration, and Pharmacokinetics — Clinic Semaglutide

Semaglutide in the clinical dose-response record

Semaglutide has the most extensively characterized dose-response relationship of any GLP-1 receptor agonist. The approved subcutaneous dose range spans 0.25 mg (initiation, tolerability assessment) through 2.4 mg weekly (weight management maintenance); an investigational 7.2 mg dose has been studied in STEP UP [17]. Oral formulations range from 7 mg daily (T2D initiation) through an investigational 50 mg daily formulation studied in OASIS 1 [6]. This page documents doses as studied and approved in the trial record.

Semaglutide Dosing Protocols in the Research Literature

The approved weight management titration schedule reflects tolerability engineering as much as pharmacological necessity. The standard protocol for subcutaneous semaglutide 2.4 mg initiates at 0.25 mg once weekly for four weeks — a dose that produces little clinical glycemic or weight effect, serving primarily to establish GI tolerability. Subsequent steps: 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), then 2.4 mg maintenance [1].

GI adverse events peak during dose escalation weeks and typically resolve within 4–8 weeks at each stable dose level [5]. Slower titration schedules — extending each step to 8 weeks instead of 4 — have been studied and used clinically in participants with higher GI sensitivity, with comparable ultimate efficacy and better tolerability during the escalation phase.

For the T2D indication, subcutaneous doses of 0.5 mg and 1.0 mg weekly were approved in 2017 and extended to 2.0 mg in later label updates. Oral semaglutide initiates at 3 mg daily for 30 days, steps to 7 mg, then optionally to 14 mg for the T2D indication.

Semaglutide Maximum Dose in Research Protocols

The approved maximum dose for weight management is 2.4 mg subcutaneous once weekly. In the 2025 STEP UP trial (N=803, 72 weeks), an investigational higher dose of 7.2 mg weekly was compared directly to the approved 2.4 mg dose and placebo [17]. Results: −18.7% mean weight reduction at 7.2 mg versus −15.6% at 2.4 mg versus −3.9% placebo. 31.2% of 7.2 mg participants achieved ≥25% weight loss.

GI adverse events were more frequent at 7.2 mg (71% vs 61% with 2.4 mg), consistent with dose-dependent GI pathway activation. The safety profile was otherwise consistent with the known class effects [17]. The 7.2 mg dose entered accelerated FDA review in 2025 following the STEP UP data. For comparative context across doses, the semaglutide dosing protocols section above covers the full titration architecture.

Semaglutide Half-Life and Pharmacokinetics

Terminal half-life: approximately 168 hours (7 days) following subcutaneous administration in humans. The range across studies is 155–183 hours. This enables once-weekly dosing and means substantial residual drug — maintaining pharmacodynamic effects — persists for approximately 5 weeks after the final dose [13].

The 168-hour half-life is the direct result of the C18 fatty diacid albumin-binding modification. Albumin-bound semaglutide is not filtered renally (albumin is above the glomerular filtration threshold), and the albumin binding also provides steric protection against DPP-4 cleavage. The Aib substitution at position 8 provides additional DPP-4 resistance at the primary cleavage site [13].

Pharmacokinetic profile summary:

  • Tmax (subcutaneous): 1–3 days post-injection
  • Tmax (oral): approximately 1 hour (fasted), with the SNAC absorption window
  • Oral bioavailability: 0.4–1% (oral 14 mg formulation in clinical conditions)
  • Protein binding: >99% (albumin-bound in plasma)
  • Volume of distribution: approximately 12.5 L (consistent with albumin-bound distribution)
  • Clearance: proteolytic (not CYP450); no significant hepatic first-pass metabolism
  • Elimination: proteolytic cleavage products excreted renally; negligible intact drug in urine

Semaglutide Half-Life and Clearance

The terminal half-life of approximately 168 hours in humans enables once-weekly subcutaneous dosing. Substantial residual drug remains for ~5 weeks after the final dose, meaning pharmacodynamic effects (appetite suppression, glycemic benefit) persist beyond discontinuation. The STEP 1 extension data showed weight regain beginning within weeks of stopping, consistent with the pharmacokinetic residual effect dissipating at the five-week mark [4].

Drug accumulation occurs across the first four to five weekly doses before steady-state plasma concentrations are reached. This explains why the earliest clinical effects (appetite suppression in the first two weeks) occur before the full steady-state plasma concentration is established — partial receptor occupancy at sub-steady-state concentrations is pharmacologically active.

For patients on concurrent oral medications, the delayed gastric emptying mechanism matters pharmacokinetically: peak plasma concentrations (Cmax) of co-administered oral drugs are delayed and reduced, but overall drug exposure (AUC) is typically unchanged — the drug is absorbed more slowly, not less completely [15]. Narrow-therapeutic-index oral drugs warrant timing consideration.

Side Effect Timing During Dose Escalation

GI adverse events peak during dose escalation phases — specifically in weeks 4–16 of a standard titration protocol, corresponding to each dose step-up (0.5 mg, 1.0 mg, 1.7 mg). Nausea is most common at initiation and at each dose step-up event; diarrhea is also elevated during step-up weeks [5].

At stable dose, GI adverse events typically self-limit within 4–8 weeks. The 4.3% treatment discontinuation rate due to GI adverse events in STEP trials reflects the approximately 5–10% subset for whom events were persistent or severe enough to interrupt the protocol despite the gradual titration schedule [5].

Practical note from the trial literature: smaller, more frequent meals during dose escalation phases reduced nausea incidence in participant subgroups in STEP trial analyses. High-fat and high-sugar foods correlated with higher GI event rates in participant-reported data.

Semaglutide Reconstitution in Research Settings

The approved subcutaneous formulation is a solution in a pre-filled pen — it does not require reconstitution. Research-grade lyophilized semaglutide (used in laboratory and investigational settings) is typically reconstituted with bacteriostatic water; standard reconstitution protocols vary by intended concentration. Reconstituted solutions are stored refrigerated and protected from light. Stability data varies by supplier and concentration; the licensed formulation's stability characteristics (refrigerated storage 2–8°C; room temperature up to 30°C for 56 days in use) are not directly applicable to reconstituted research-grade material.

This site documents what the trial record and pharmacological literature describe. It does not provide reconstitution protocols, sourcing guidance, or clinical preparation advice.

Semaglutide Starting Dose and Titration Schedule

Research protocols and the approved label for the weight management indication initiate at 0.25 mg subcutaneous once weekly for four weeks. This dose level produces minimal clinical glycemic or weight effect; its function is tolerability assessment before the first efficacy-relevant dose step [1].

Standard approved titration for weight management:

  • Weeks 1–4: 0.25 mg/week
  • Weeks 5–8: 0.5 mg/week
  • Weeks 9–12: 1.0 mg/week
  • Weeks 13–16: 1.7 mg/week
  • Week 17 onward: 2.4 mg/week (maintenance)

Slower titration schedules (8 weeks per step rather than 4) have been studied in participants with higher GI sensitivity, producing comparable efficacy at maintenance dose. The dose-escalation architecture is a deliberate tolerability strategy rather than a requirement for pharmacological efficacy onset.